{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:31:08Z","timestamp":1773786668562,"version":"3.50.1"},"reference-count":30,"publisher":"Tech Science Press","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2025.061905","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T05:13:05Z","timestamp":1745471585000},"page":"1667-1677","source":"Crossref","is-referenced-by-count":1,"title":["Tyrosine kinase inhibitors in first-line treatment of advanced NSCLC with epidermal growth factor receptor mutations: Real-world data from Vietnam"],"prefix":"10.32604","volume":"33","author":[{"given":"KHANH TOAN","family":"NGUYEN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"THI HUONG","family":"PHAM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VAN LAM","family":"NGO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VAN TUAN","family":"BUI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VAN NHAT","family":"NGUYEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"THI PHUONG THAO","family":"NGUYEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"THI KHANH HA","family":"NGUYEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"THI THUY VAN","family":"NGUYEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","unstructured":"Support IARC in the fight against cancer\u2014IARC. [Internet]. [cited 2025 Mar 16]. Available from: https:\/\/www.iarc.who.int\/donate\/."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.jtho.2021.06.002","article-title":"Lung cancer in Vietnam","volume":"16","author":"Tran","year":"2021","journal-title":"J Thorac Oncol"},{"key":"ref3","first-page":"48","article-title":"Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update","volume":"2","author":"Bethune","year":"2010","journal-title":"J Thorac Dis"},{"key":"ref4","article-title":"ALK inhibitors: moving rapidly from discovery to clinical approval and beyond","volume":"13","author":"Jane de Lartigue","year":"2012","journal-title":"Oncol Live"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/modpathol.2013.192","article-title":"Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers","volume":"27","author":"Yoshida","year":"2014","journal-title":"Mod Pathol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non\u2013small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","article-title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1158\/1078-0432.CCR-06-0658","article-title":"Update on epidermal growth factor receptor mutations in nonsmallcell lung cancer","volume":"12","author":"Riely","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"102080","DOI":"10.1016\/j.canep.2021.102080","article-title":"Uncommon EGFR mutations in non-small-cell lung cancer: a systematic literature review of prevalence and clinical outcomes","volume":"76","author":"John","year":"2022","journal-title":"Cancer Epidemiol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.19.00931","article-title":"Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II Trial (KCSG-LU15-09)","volume":"38","author":"Cho","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3390\/cancers16061079","article-title":"A real-world study of patient characteristics and clinical outcomes in EGFR mutated lung cancer treated with first-line osimertinib: expanding the FLAURA trial results into routine clinical practice","volume":"16","author":"Viray","year":"2024","journal-title":"Cancers"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.21037\/tlcr-21-501","article-title":"Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea","volume":"10","author":"Lee","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1758835921996509","DOI":"10.1177\/1758835921996509","article-title":"Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer","volume":"13","author":"Magios","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"v631","DOI":"10.1093\/annonc\/mdz260.060","article-title":"Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC","volume":"30","author":"Christopoulos","year":"2019","journal-title":"Ann Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.2217\/fon-2020-0740","article-title":"Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final aanalysis of the GioTag study","volume":"16","author":"Hochmair","year":"2020","journal-title":"Future Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"S1405","DOI":"10.1016\/j.annonc.2020.10.466","article-title":"420TiP UpSwinG: real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib","volume":"31","author":"Miura","year":"2020","journal-title":"Ann Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4143\/crt.2018.117","article-title":"Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res Treat off J Korean Cancer Assoc"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2021.09.041","article-title":"Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)","volume":"159","author":"Sakata","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"100058","DOI":"10.1016\/j.esmorw.2024.100058","article-title":"Real-world outcomes of treatment strategy between first-line osimertinib, first\/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC","volume":"5","author":"Uehara","year":"2024","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/annonc\/mds214","article-title":"Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-na\u00efve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)","volume":"24","author":"Inoue","year":"2013","journal-title":"Ann Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1038\/s41598-020-61571-5","article-title":"Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: a disproportionality analysis of FDA adverse event reporting system","volume":"10","author":"Huang","year":"2020","journal-title":"Sci Rep"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"103305","DOI":"10.1016\/j.critrevonc.2021.103305","article-title":"Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: a systematic review and network meta-analysis","volume":"160","author":"Zhao","year":"2021","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-7\/OncolRes-33-07-61905\/OncolRes-33-61905.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T01:39:42Z","timestamp":1763343582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n7\/62634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2025.061905","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}